Fair value · BELITE BIO, INC (BLTE) · updated 2026-09-13 · from 20-F FY2025
BELITE BIO (BLTE): not enough filed data to read assumptions out of the price yet.
These methods need positive earnings and cash flow from the company’s SEC filings. The detailed valuation tools below still work with whatever has been filed.
The filing behind these numbers
BELITE BIO, INC- Revenue
- $0
- Diluted EPS
- $-2.31
- Free cash flow
- $-37.1M
- operating cash flow − capital expenditure
- Diluted shares
- 33.5M
- weighted average
20-F FY2025 · fiscal year ended 2025-12-31 · filed 2026-03-31 · accession 0001104659-26-037374
Open this filing on sec.govNeed BLTE data in your own agent or pipeline?
The valuation data behind this page — DCF fair value, margin of safety, PE vs industry, analyst estimates — is also available programmatically through the EvidInvest MCP server & financial data API for Claude, Cursor, or any MCP client and HTTP pipeline.